person · Reporting owner
Pacelli Steven Robert
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Managing Director Dexcom V | November 24, 2023 | November 27, 2023 |
| ProSomnus, Inc.OSA · Entity 94197 | Director | December 06, 2022 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date November 24, 2023 · Filed November 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,775 |
Reported balance
After 2023-11-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-11-24 · Sale · Disposed 411 · Balance 124,775 F1: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
F2: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
ProSomnus, Inc.
Report date December 06, 2022 · Filed February 16, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,200 |
Reported balance
Holding disclosure · report date 2022-12-06 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 18,200 F1: Holdings have been adjusted to rectify unintentional underreporting in the Reporting Person's Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings have been adjusted to rectify unintentional underreporting in the Reporting Person's Form 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2020 Filed Jul 27, 2020 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 583 | $429.54 | $250,420.60 |
DisclosureSEC source: 0001093557-20-000210 · edgardoc.xml · nonDerivative · entry 5 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,408 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $428.83 to $429.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 211 | $428.10 | $90,328.47 |
DisclosureSEC source: 0001093557-20-000210 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,991 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $427.83 to $428.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 437 | $427.21 | $186,691.43 |
DisclosureSEC source: 0001093557-20-000210 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,202 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $426.49 to $427.26. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $424.50 | $42,450.00 |
DisclosureSEC source: 0001093557-20-000210 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,639 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $421.62 | $84,323.00 |
DisclosureSEC source: 0001093557-20-000210 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,739 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 111 | $411.96 | $45,727.56 |
DisclosureSEC source: 0001093557-20-000197 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,939 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 657 | $410.26 | $269,541.87 |
DisclosureSEC source: 0001093557-20-000197 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,050 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $409.88 to $410.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 444 | $408.99 | $181,590.01 |
DisclosureSEC source: 0001093557-20-000197 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,707 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $408.73 to $409.25. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 319 | $407.18 | $129,890.26 |
DisclosureSEC source: 0001093557-20-000197 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,151 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $407.09 to $407.37. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| May 22, 2020 Filed May 27, 2020 22:06 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,531 | $396.74 | $607,408.94 |
DisclosureSEC source: 0001093557-20-000172 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,470 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 20:51 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,531 | $318.57 | $487,730.67 |
DisclosureSEC source: 0001093557-20-000132 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,001 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 22:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,300 | $209.55 | $272,415.00 |
DisclosureSEC source: 0001093557-20-000111 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,532 F3 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 22:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 75 | $208.02 | $15,601.50 |
DisclosureSEC source: 0001093557-20-000111 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,832 F3 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 22:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 156 | $207.17 | $32,318.69 |
DisclosureSEC source: 0001093557-20-000111 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,907 F3 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $207.01 to $207.54. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 13, 2020 Filed Mar 25, 2020 22:22 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-20-000111 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,063 F1 · shares: The transaction represents a gift by the Reporting Person of 2,250 shares to a charitable donor advised fund. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:11 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,733 | $265.43 | $2,052,539.26 |
DisclosureSEC source: 0001093557-20-000087 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,313 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:11 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 313 | $250.02 | $78,256.26 |
DisclosureSEC source: 0001093557-20-000087 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,046 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $250.02 to $250.0201. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 11, 2020 Filed Mar 14, 2020 01:11 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3 | $246.25 | $738.76 |
DisclosureSEC source: 0001093557-20-000087 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,359 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $246.05 to $246.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 08, 2020 Filed Mar 10, 2020 23:26 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 8,811 | $0.00 | $8.81 |
DisclosureSEC source: 0001093557-20-000062 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,362 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 31,636 unvested restricted stock units, 8,811 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 9,991 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 21:11 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 8,927 | $0.00 Strike: $9.80 | $0.00 |
DisclosureSEC source: 0001093557-20-000047 · edgardoc.xml · derivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,927 shares Expires 2020-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 21:11 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 8,927 | $9.80 | $87,484.60 |
DisclosureSEC source: 0001093557-20-000047 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:24 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 138 | $283.06 | $39,062.74 |
DisclosureSEC source: 0001093557-20-000039 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,624 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $282.73 to $283.19. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:24 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 483 | $278.32 | $134,428.27 |
DisclosureSEC source: 0001093557-20-000039 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,762 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $278.19 to $278.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:24 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 540 | $277.41 | $149,799.24 |
DisclosureSEC source: 0001093557-20-000039 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,245 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $277.025 to $277.62. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:24 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 370 | $275.76 | $102,032.94 |
DisclosureSEC source: 0001093557-20-000039 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,785 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $275.585 to $275.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 22:06 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 500 | $236.03 | $118,012.55 |
DisclosureSEC source: 0001093557-20-000013 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,155 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $236.00 to $236.17. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 22:06 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $234.26 | $70,278.99 |
DisclosureSEC source: 0001093557-20-000013 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,655 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $234.06 to $234.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 22:06 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 732 | $233.17 | $170,679.93 |
DisclosureSEC source: 0001093557-20-000013 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,955 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $232.53 to $233.39. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| December 23, 2019 Filed Dec 24, 2019 00:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $213.65 | $42,730.00 |
DisclosureSEC source: 0001093557-19-000263 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,687 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $213.63 to $213.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| December 23, 2019 Filed Dec 24, 2019 00:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,332 | $213.10 | $283,846.14 |
DisclosureSEC source: 0001093557-19-000263 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,887 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $212.61 to $213.59. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 00:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 232 | $218.52 | $50,696.06 |
DisclosureSEC source: 0001093557-19-000248 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,219 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $218.11 to $218.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 00:42 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,300 | $217.39 | $282,604.01 |
DisclosureSEC source: 0001093557-19-000248 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,451 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $217.06 to $217.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 20:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 210 | $153.34 | $32,202.24 |
DisclosureSEC source: 0001093557-19-000226 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,751 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $153.34 to $153.43. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 20:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 681 | $152.71 | $103,996.53 |
DisclosureSEC source: 0001093557-19-000226 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,961 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $152.21 to $153.13. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 20:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 641 | $151.69 | $97,236.37 |
DisclosureSEC source: 0001093557-19-000226 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,642 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $151.18 to $152.16. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 23:37 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 532 | $156.15 | $83,070.58 |
DisclosureSEC source: 0001093557-19-000217 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,283 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $155.80 to $156.61. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 23:37 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,000 | $155.11 | $155,110.00 |
DisclosureSEC source: 0001093557-19-000217 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,815 F1 · shares: On June 11, 2019, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $154.35 to $155.20. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,525 | $150.11 | $829,363.83 |
DisclosureSEC source: 0001093557-19-000195 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,815 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 01:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 318 | $145.46 | $46,255.90 |
DisclosureSEC source: 0001093557-19-000195 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,340 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $145.4585 to $145.4592. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 38,823 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 19,251 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 4,585 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 21:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $151.69 | $60,676.52 |
DisclosureSEC source: 0001093557-19-000166 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,658 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $151.55 to $151.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 21:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,000 | $150.20 | $150,204.00 |
DisclosureSEC source: 0001093557-19-000166 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,058 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $149.84 to $150.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 21:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,716 | $148.85 | $255,423.34 |
DisclosureSEC source: 0001093557-19-000166 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,058 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $148.41 to $149.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 800 | $117.70 | $94,160.00 |
DisclosureSEC source: 0001093557-19-000129 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,774 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,285 | $116.93 | $150,256.59 |
DisclosureSEC source: 0001093557-19-000129 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,574 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $116.64 to $117.55. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,512 | $116.01 | $175,399.86 |
DisclosureSEC source: 0001093557-19-000129 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,859 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $115.55 to $116.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| April 23, 2019 Filed Apr 24, 2019 23:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,300 | $117.21 | $152,375.99 |
DisclosureSEC source: 0001093557-19-000109 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,371 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $117.00 to $117.25. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| April 23, 2019 Filed Apr 24, 2019 23:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,296 | $116.27 | $266,952.94 |
DisclosureSEC source: 0001093557-19-000109 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,671 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $115.75 to $116.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 22:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,227 | $140.56 | $172,467.12 |
DisclosureSEC source: 0001093557-19-000089 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,967 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $140.20 to $140.68. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 22:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,369 | $139.77 | $331,103.76 |
DisclosureSEC source: 0001093557-19-000089 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,194 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $139.20 to $140.19. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-19-000084 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,563 F3 · shares: This transaction represents a gift of securities made by the reporting person. This is not a market transaction, thus no price has been reported. Transferor retains no beneficial or voting interest in the transferred shares. F2 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.